KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Short term Debt: 2018-2024

Historic Short term Debt for Aquestive Therapeutics (AQST) over the last 6 years, with Dec 2024 value amounting to $26,000.

  • Aquestive Therapeutics' Short term Debt rose 25208.00% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 25208.00%. This contributed to the annual value of $26,000 for FY2024, which is 18.18% up from last year.
  • Aquestive Therapeutics' Short term Debt amounted to $26,000 in FY2024, which was up 18.18% from $22,000 recorded in FY2023.
  • Aquestive Therapeutics' 5-year Short term Debt high stood at $18.7 million for FY2022, and its period low was $22,000 during FY2023.
  • Its 3-year average for Short term Debt is $6.2 million, with a median of $26,000 in 2024.
  • As far as peak fluctuations go, Aquestive Therapeutics' Short term Debt surged by 823.46% in 2022, and later plummeted by 99.88% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Short term Debt (Yearly) stood at $2.6 million in 2020, then dropped by 21.36% to $2.0 million in 2021, then spiked by 823.46% to $18.7 million in 2022, then plummeted by 99.88% to $22,000 in 2023, then increased by 18.18% to $26,000 in 2024.